We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-8.83%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.57B
AUM Growth
-$614M
Cap. Flow
+$51.4M
Cap. Flow %
1.44%
Top 10 Hldgs %
48.82%
Holding
78
New
14
Increased
15
Reduced
33
Closed
9
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$73M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$72.6M
3
ONEM
1Life Healthcare
ONEM
+$68.5M
4
MRK icon
Merck
MRK
+$64.9M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$53.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$116M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$109M
3
BSX icon
Boston Scientific
BSX
+$73.8M
4
CNC icon
Centene
CNC
+$44.2M
5
HCA icon
HCA Healthcare
HCA
+$42.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Industrials 0.87%
3 Miscellaneous 0.25%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
$46.8M 1.31%
2,126,600
-2,500
-0.1% -$80.3K
2018 Q2
7 quarters
NGNE icon
27
Neurogene
NGNE
$465M
$46M 1.29%
202,061
+106,019
+110% +$21.8M
2019 Q4
1 quarter
KRYS icon
28
Krystal Biotech
KRYS
$9.37B
$45.5M 1.28%
1,051,800
-38,400
-4% -$2.01M
2018 Q4
5 quarters
ATRA icon
29
Atara Biotherapeutics
ATRA
$92.1M
$45M 1.26%
211,735
+25,792
+14% +$8.19M
2014 Q4
21 quarters
AXNX icon
30
DELISTED
Axonics, Inc. Common Stock
AXNX
$38.3M 1.07%
1,507,400
-24,600
-2% -$732K
2018 Q4
5 quarters
PRAH
31
DELISTED
PRA Health Sciences, Inc.
PRAH
$36.8M 1.03%
442,700
-7,100
-2% -$692K
2019 Q3
2 quarters
SRRK icon
32
Scholar Rock
SRRK
$4.86B
$35M 0.98%
2,890,089
-50,800
-2% -$683K
2018 Q2
7 quarters
DXCM icon
33
DexCom
DXCM
$32.5B
$34.8M 0.98%
+517,200
New +$32.2M
2020 Q1
0 quarters
EIDX
34
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$33.8M 0.95%
689,478
-11,700
-2% -$596K
2018 Q2
7 quarters
GMAB icon
35
Genmab
GMAB
$22.8B
$32.8M 0.92%
1,549,000
+612,300
+65% +$13.6M
2019 Q3
2 quarters
AMED icon
36
DELISTED
Amedisys
AMED
$32.6M 0.91%
177,565
-3,500
-2% -$623K
2019 Q2
3 quarters
CYRX icon
37
CryoPort
CYRX
$853M
$31M 0.87%
1,817,663
+975,300
+116% +$17.1M
2019 Q4
1 quarter
ZYME icon
38
Zymeworks
ZYME
$1.8B
$30.8M 0.86%
+868,600
New +$35.5M
2020 Q1
0 quarters
REPL icon
39
Replimune Group
REPL
$1.02B
$29.7M 0.83%
2,980,493
+214,086
+8% +$3.19M
2018 Q3
6 quarters
WVE icon
40
Wave Life Sciences
WVE
$617M
$27.4M 0.77%
2,927,352
-399,141
-12% -$3.4M
2015 Q4
17 quarters
CTLT icon
41
DELISTED
CATALENT, INC.
CTLT
$26.3M 0.74%
+506,300
New +$27.6M
2020 Q1
0 quarters
PPD
42
DELISTED
PPD, Inc. Common Stock
PPD
$23M 0.64%
+1,290,832
New +$32.4M
2020 Q1
0 quarters
ARDX icon
43
Ardelyx
ARDX
$798M
$22.2M 0.62%
3,904,100
-95,900
-2% -$652K
2019 Q4
1 quarter
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$19.5M 0.55%
708,038
-82,033
-10% -$2.39M
2017 Q4
9 quarters
BCEL
45
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$18.7M 0.52%
1,128,806
-8,000
-0.7% -$145K
2019 Q2
3 quarters
SWAV icon
46
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$18.5M 0.52%
557,800
-10,100
-2% -$401K
2019 Q4
1 quarter
TWST icon
47
Twist Bioscience
TWST
$8.8B
$18M 0.51%
+590,200
New +$15.9M
2020 Q1
0 quarters
GRTS icon
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.9M 0.5%
3,068,194
-48,400
-2% -$406K
2018 Q3
6 quarters
HOOK icon
49
DELISTED
HOOKIPA Pharma
HOOK
$15.4M 0.43%
186,251
-3,001
-2% -$329K
2019 Q2
3 quarters
TCRR
50
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$13.7M 0.38%
1,767,288
-31,900
-2% -$390K
2019 Q1
4 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return
TIA
Tandem Investment Advisors Charleston, South Carolina $1.49B AUM 12.33% 1-Year Est. Return

Redmile Group's Q1 2020 Portfolio in Review

As of Q1 2020, Redmile Group held 78 positions worth $3.57B, down 15% from $4.18B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q1 2020 filing shows 14 new, 15 increased, 33 reduced and 9 closed positions. Its largest new stake was Beam Therapeutics: 3,359,258 shares worth $60.5M. The largest sale was Bristol-Myers Squibb, an estimated $116M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Miscellaneous.

  • Redmile Group's largest Q1 2020 buy was Beam Therapeutics: 3,359,258 shares worth $60.5M.
  • Redmile Group added most to Momenta Pharmaceuticals, Inc. in Q1 2020, an estimated $53.9M increase.
  • Redmile Group's biggest Q1 2020 reduction was Centene, cutting an estimated $44.2M.
  • Redmile Group fully exited Bristol-Myers Squibb in Q1 2020, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 49% of its $3.57B portfolio in Q1 2020.
  • Redmile Group opened 14 new positions and closed 9 in Q1 2020.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $3.57B.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.